Oncology Archives - Page 5 of 22

Cost-effectiveness of Nivolumab plus Ipilimumab for the first-line treatment of intermediate/poor-risk advanced and/or metastatic renal cell carcinoma in Switzerland

Authors: E Çakar, C Oniangue-Ndza, R P Schneider, S L Klijn, U M Vogl, C Rothermundt, J R May Published: PharmacoEconomics – open, 2023 View publication Objective This study assessed the cost-effectiveness...

Quality-adjusted time without symptoms or toxicity: analysis of axicabtagene ciloleucel versus standard of care in patients with relapsed/refractory large b-cell lymphoma: Q-TWiST analysis of axi-cel versus standard of care

Authors: M J Kersten, Y Qiao, R Shah, C Solem, J T Snider, C To, P Cheng, C Spooner, M-A Perales Published: Transplantation and cellular therapy, 2023 View publication Background The quality-adjusted...

A probabilistic cost-effectiveness analysis of Venetoclax and Obinutuzumab as a first-line therapy in chronic lymphocytic leukemia in Canada

Authors: A Chatterjee, G van de Wetering, R Goeree, C Owen, A M Desbois, S Barakat, B S Manzoor, K Sail Published: PharmacoEconomics – Open, 2022 View publication Background Venetoclax is a...

Delphi panel for consensus on the optimal management of dabrafenib plus trametinib-related pyrexia in patients with melanoma

Authors: R Frazer, A Gupta, C Herbert, M Payne, S Diaz-Mendoza, S-A Vincent, E Kovaleva Published: Therapeutic Advances in Medical Oncology, 2022 View publication Purpose Dabrafenib and trametinib combination therapy (dab +...

Treatment patterns and real-world clinical outcomes in patients with advanced endometrial cancer who are microsatellite instability (MSI)-high or are mismatch repair deficient (dMMR) in the United States

Authors: S S Kelkar, V S Prabhu, S Corman, S Odak, N Rusibamayila, C Macahilig, R Orlowski, L Duska Published: Gynecologic Oncology, 2022 View publication Objectives Microsatellite instability-high (MSI-H) and deficient DNA...

Considerations for the utility of real-world evidence beyond trial data in advanced NSCLC: the case of frontline tyrosine kinase inhibitors

Authors: P Gaitonde, V Chirikov, S Kelkar, B Liljas Published: Dove Medical Press, 2022 View publication Background To extend the discussion on the use of real-world evidence (RWE) in conveying the clinical...

Real-world clinical effectiveness and safety of CT-P10 in patients with diffuse large B-cell lymphoma: An observational study in Europe

Authors: MJ Bishton, G Salles, C Golfier, W Knauf, M Bocchia, D Turner, B Slama, J Harchowal, S Marshall, A Bosi, JJ Lleonart Published: eJHaem, 2022 View publication Abstract The rituximab biosimilar...

Understanding what matters to metastatic castration-resistant prostate cancer (mCRPC) patients when considering treatment options: A US patient preference survey

Authors: D J George, A F Mohamed, J-H Tsai, M Karimi, N Ning, S Jayade, M Botteman Published: Cancer Medicine, 2022 View publication Background Understanding how patients perceive the efficacy, safety, and...

Cost and clinical benefits associated with Oncotype DX® test in patients with early-stage HR+/HER2- node-negative breast cancer in the Netherlands

Authors: F E de Jongh, R Efe, K H Herrmann, J A Spoorendonk Published: International Journal of Breast Cancer, 2022 View publication Objectives Patients with early-stage HR+/HER2- N0 breast cancer may receive...

News